ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RYTM Rhythm Pharmaceuticals Inc

38.01
-0.10 (-0.26%)
Apr 19 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 615,980
Bid Price 35.00
Ask Price 39.00
News -
Day High 39.10

Low
15.5001

52 Week Range

High
52.57

Day Low 36.92
Company Name Stock Ticker Symbol Market Type
Rhythm Pharmaceuticals Inc RYTM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.10 -0.26% 38.01 20:00:00
Open Price Low Price High Price Close Price Prev Close
37.79 36.92 39.10 38.01 38.11
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,959 615,980 $ 37.69 $ 23,218,167 - 15.5001 - 52.57
Last Trade Time Type Quantity Stock Price Currency
19:23:22 17 $ 39.00 USD

Rhythm Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.29B 60.14M - 77.43M -184.68M -3.07 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Rhythm Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RYTM Message Board. Create One! See More Posts on RYTM Message Board See More Message Board Posts

Historical RYTM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week42.0142.0936.9239.30586,186-4.00-9.52%
1 Month40.6743.6836.9240.78527,247-2.66-6.54%
3 Months44.6852.5736.9243.47589,570-6.67-14.93%
6 Months23.4152.5721.3440.05668,87614.6062.37%
1 Year20.6952.5715.500130.05685,80317.3283.71%
3 Years19.4452.573.0419.86755,08018.5795.52%
5 Years26.0352.573.0420.69566,78111.9846.02%

Rhythm Pharmaceuticals Description

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Your Recent History

Delayed Upgrade Clock